Welcome to our dedicated page for Tonix Pharmaceuticals Holding news (Ticker: TNXP), a resource for investors and traders seeking the latest updates and insights on Tonix Pharmaceuticals Holding stock.
Tonix Pharmaceuticals Holding Corp. (symbol: TNXP) is a pioneering biopharmaceutical company dedicated to developing, licensing, and commercializing innovative therapeutics to treat and prevent human diseases. With a focus on central nervous system (CNS) disorders, Tonix is at the forefront of addressing major public health challenges.
One of Tonix's key projects is Tonmya, aimed at treating PTSD, which is currently in advanced stages of development. Additionally, the company is working on TNX-601 (tianeptine oxalate), a daytime treatment for PTSD, and TNX-801, a synthetic version of the horsepox virus, intended as a potential smallpox vaccine, both at the pre-IND (Investigational New Drug) application stage.
The company’s immunology development portfolio includes TNX-1500, a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154), being developed to prevent allograft rejection and treat autoimmune diseases. This portfolio demonstrates Tonix's commitment to addressing both organ transplant rejection and autoimmunity, as well as cancer.
Tonix’s mission to alleviate suffering extends beyond CNS disorders and immunology, as it is also exploring therapeutic solutions for rare and infectious diseases. Their dedication to research and innovation has established partnerships with reputable institutions, such as Massachusetts General Hospital, ensuring that their projects are backed by cutting-edge science and expertise.
For more information, visit Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced a securities purchase agreement with institutional investors to sell 2.5 million shares of Series A and 500,000 shares of Series B convertible redeemable preferred stock at $9.50 per share, totaling $30 million in gross proceeds. Each preferred share is convertible into common stock at $4.00, contingent upon shareholder approval to increase common stock authorization from 50 million to 150 million. The offering is expected to close on June 24, 2022. A.G.P./Alliance Global Partners is the placement agent for this offering.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced the publication of a study demonstrating the enhanced analgesic effects of intranasal oxytocin when combined with magnesium (Mg2+) in animal models. This patented technology underpins their drug candidates, TNX-1900 for migraine prevention and TNX-2900 for treating hyperphagia in Prader-Willi syndrome. The issued patents are expected to ensure market exclusivity until 2036. The CEO stated that the magnesium-enhanced formulation may eliminate dose-related analgesic inconsistencies, potentially offering a non-addictive treatment alternative for migraine and craniofacial pain.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced the opening of its new 45,000 sq ft Advanced Development Center (ADC) in North Dartmouth, Massachusetts, on June 21, 2022. The facility will enhance the company's ability to manufacture clinical quality vaccines for infectious diseases such as monkeypox, smallpox, and COVID-19. The ADC includes state-of-the-art bioreactors and is designed to support U.S. pandemic preparedness. With the capability to employ 70 staff, this facility is a significant step toward accelerating vaccine development and production.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) unveiled promising data on its TNX-1500 monoclonal antibody at the 2022 American Transplant Congress. The research, conducted by Massachusetts General Hospital, shows that TNX-1500 effectively prevents organ transplant rejection in non-human primates, demonstrating both efficacy and safety. Tonix's CEO highlighted the need for improved treatments in this area, as no effective humanized anti-CD40L antibody exists yet. The company is actively moving into Phase 1 studies for TNX-1500 and continues its development approach across various therapeutic areas.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced an oral presentation highlighting the activity of Wnt/β-Catenin signaling pathway inhibitors against SARS-CoV-2. Presented by Dr. Tom Hobman at the Canadian Society for Virology, the research revealed that these inhibitors reduced lung infection in an animal model. The presentation included promising data on these drugs, some of which have been studied in humans or are FDA approved. Tonix aims to advance these candidates towards clinical testing, indicating a strategic focus on broad-spectrum antiviral development.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced a successful presentation of preclinical data for its vaccine TNX-801 at the 4th Symposium of the Canadian Society for Virology on June 5, 2022. The study demonstrated that all vaccinated macaques achieved sterilizing immunity against monkeypox following exposure. The data, presented by researchers from Tonix and the University of Alberta, highlights the vaccine's potential to combat rising monkeypox cases globally. TNX-801 is based on synthetic horsepox and aims to provide protection against both monkeypox and smallpox.
Tonix Pharmaceuticals (Nasdaq: TNXP) will present at the 2022 BIO International Convention scheduled for June 13-16 in San Diego, CA. The presentation is set for June 13 at 3:45 p.m. PT. Tonix focuses on developing therapeutics in areas such as central nervous system disorders and infectious diseases. Key projects include TNX-102 SL for fibromyalgia and Long COVID, TNX-1300 for cocaine intoxication, and vaccines for smallpox and COVID-19. As a clinical-stage biopharmaceutical company, Tonix's product candidates are investigational and have not yet received FDA approval.
Tonix Pharmaceuticals (Nasdaq: TNXP) announced it has regained compliance with Nasdaq's minimum bid price requirement, having maintained a closing bid price of $1.00 or above for 10 consecutive business days as of June 1, 2022. This compliance closure means Tonix can continue its listing on The Nasdaq Capital Market. The company is actively advancing multiple clinical-stage candidates, including treatments for fibromyalgia and Long COVID, while also working on vaccines for smallpox, monkeypox, and COVID-19.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced the issuance of U.S. Patent No. 11,345,896 on May 31, 2022, by the USPTO. This patent secures synthetic horsepox virus technology crucial for its TNX-801 vaccine, aimed at combating monkeypox and smallpox. Additionally, TNX-1840 and TNX-1850 are in development targeting COVID-19 variants. The new patent enhances Tonix's vaccine pipeline and provides market exclusivity until 2037, underscoring its leadership in synthetic biology and the potential for advancing innovative vaccines.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) has launched a $12.5 million share repurchase program aimed at buying back its common stock from the open market and through private negotiations, based on market conditions. Funding will come from available cash. The program may be adjusted or halted depending on market evaluations and is expected to enhance shareholder value by reducing the number of outstanding shares. This announcement follows the recent advancements in Tonix's clinical-stage pipeline, specifically in CNS and infectious diseases.
FAQ
What is the current stock price of Tonix Pharmaceuticals Holding (TNXP)?
What is the market cap of Tonix Pharmaceuticals Holding (TNXP)?
What is the main focus of Tonix Pharmaceuticals Holding Corp.?
What is Tonmya?
What are TNX-601 and TNX-801?
What is TNX-1500?
Which institutions is Tonix Pharmaceuticals affiliated with?
How can I get more information about Tonix Pharmaceuticals?
What areas of disease does Tonix Pharmaceuticals focus on?
What stage are TNX-601 and TNX-801 in?
Who can I contact for investor relations at Tonix Pharmaceuticals?
Who can I contact for media inquiries at Tonix Pharmaceuticals?
